| [25] |
Ju KC, Zhang B, Hu YL, et al. High expression of G protein subunit gamma 13 is associated with poor prognosis of gastrointestinal stromal tumor[J]. Pathol Res Pract, 2020, 216(10): 153143.
|
| [1] |
Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour[J]. Lancet, 2007, 369(9574): 1731-1741.
|
| [2] |
Gheorghe G, Bacalbasa N, Ceobanu G, et al. Gastrointestinal Stromal Tumors-A Mini Review[J]. J Pers Med, 2021, 11(8): 694.
|
| [3] |
Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours(GIST): A systematic review of population-based cohort studies[J]. Cancer Epidemiol, 2016, 40(2): 39-46.
|
| [4] |
El Rassy E, Nasr F, Assi T, et al. Epidemiology and Survival Analysis of Gastrointestinal Stromal Tumors in Lebanon: Real-life study from a Hospital tumor registry 2000-2015[J]. Gulf J Oncolog, 2017, 1(24): 38-42.
|
| [5] |
Landi B, Blay JY, Bonvalot S, et al. Gastrointestinal stromal tumours(GISTs):French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up(SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)[J]. Dig Liver Dis, 2019, 51(9): 1223-1231.
|
| [6] |
Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours:ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv68-iv78.
|
| [7] |
Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial[J]. JAMA Oncol, 2017, 3(5): 602-609.
|
| [8] |
Joensuu H, Eriksson M, Sundby Hall K, et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up[J]. JAMA Oncol, 2020, 6(8): 1241-1246.
|
| [9] |
Wu CE, Tzen CY, Wang SY, et al. Clinical Diagnosis of Gastrointestinal Stromal Tumor(GIST): From the Molecular Genetic Point of View[J]. Cancers(Basel), 2019, 11(5): 679.
|
| [10] |
Kankanamge D, Tennakoon M, Karunarathe A, et al. G protein gamma subunit, a hidden master regulator of GPCR signaling[J]. J Biol Chem, 2022, 298(12): 102618.
|
| [11] |
Takauji Y, Kudo I, En A, et al. GNG11(G-protein subunit γ 11)suppresses cell growth with induction of reactive oxygen species and abnormal nuclear morphology in human SUSM-1 cells[J]. Biochem Cell Biol, 2017, 95(4): 517-523.
|
| [12] |
Khan SM, Sleno R, Gora S, et al. The expanding roles of Gβγ subunits in G protein-coupled receptor signaling and drug action[J].Pharmacol Rev, 2013, 65(2): 545-577.
|
| [13] |
Yuan Z, Ren R, Xu Z. G protein subunit gamma 5 promotes the proliferation, metastasis and glycolysis of breast cancer cells through the Wnt/β-catenin pathway[J]. Anticancer Drugs, 2022, 33(10): 1004-1011.
|
| [14] |
Liu Y, Gu S, Wu T, et al. High GNG13 expression is associated with poor survival in epithelial ovarian cancer and breast cancer[J].Neoplasma, 2022, 69(1): 183-192.
|
| [15] |
Wei Q, Miao T, Zhang P, et al. Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates[J]. Front Genet, 2022, 13(9): 984575.
|
| [16] |
Zhou B, Zhu W, Yuan S, et al. High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma[J]. Thorac Cancer, 2022, 13(3): 369-379.
|
| [17] |
Liang L, Huang J, Yao M, et al. GNG4 Promotes Tumor Progression in Colorectal Cancer[J]. J Oncol, 2021, 10: 9931984.
|
| [18] |
Tanaka H, Kanda M, Miwa T, et al. G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer[J]. Br J Cancer, 2021,125(2): 220-228.
|
| [19] |
Zhu D, Gu X, Lin Z, et al. High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis[J]. Oncogenesis, 2021, 10(5): 43.
|
| [20] |
Zhao H, Sheng D, Qian Z, et al. Identifying GNG4 might play an important role in colorectal cancer TMB[J]. Cancer Biomark, 2021,32(4): 435-450.
|
| [21] |
《胃肠间质瘤病理诊断临床实践指南(2022版)》编写专家委员会.胃肠间质瘤病理诊断临床实践指南(2022版)[J]. 中华病理学杂志,2022, 51(10): 959-969.
|
| [22] |
Sharp RM, Ansel HJ, Keel SB. Best cases from the AFIP:gastrointestinal stromal tumor. Armed Forces Institute of Pathology[J]. Radiographics, 2001, 21(6): 1557-1560.
|
| [23] |
Wang H, Yu L, Cui Y, et al. G Protein Subunit Gamma 5 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma[J]. Dis Markers, 2022, 5: 1313359.
|
| [24] |
Zhang W, Liu Z, Liu B, et al. GNG5 is a novel oncogene associated with cell migration, proliferation, and poor prognosis in glioma[J].Cancer Cell Int, 2021, 21(1): 297.
|